Skip to content
Sign in

CSBR · NASDAQ

Champions Oncology (CSBR) Stock Price & Fundamentals

$400.01−0.50%−$2.01End-of-day price as of Oct 9, 2026

Champions Oncology (CSBR) closed at $400.01 on Oct 9, 2026, down 0.50% from the previous close of $402.02.

Share price, past year

1Y +0.78%

52-week range $352.29 – $433.09. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$400.01
Sep 30, 2026$410.90
Aug 31, 2026$384.04
Jul 31, 2026$395.85
Jun 30, 2026$431.44
May 29, 2026$402.77
Apr 30, 2026$389.16
Mar 31, 2026$359.42
Feb 27, 2026$380.99
Jan 30, 2026$375.04
Dec 31, 2025$373.67
Nov 28, 2025$388.21
Oct 31, 2025$401.66

Key statistics

Market cap
$5.57B
P/E (TTM)
—
EPS (TTM)
−$0.08
Revenue (TTM)
$60.66M
Net income (TTM)
−$1.14M
Shares outstanding
13.9M
Dividend yield
—
52-week range
$352.29 – $433.09

Champions Oncology's market cap is $5.57B, based on a share price of $400.01 and 13.9M shares outstanding as of Jul 31, 2026.

Financials

Champions Oncology reported revenue of $59.43M for fiscal 2026, up 4.36% from fiscal 2025.

Champions Oncology reported a net loss of $1.18M in fiscal 2026.

Fiscal 2026 revenue was the highest in the 10 years shown.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Annual revenue by fiscal year; the table below lists the values.
Champions Oncology annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2026ended Apr 30, 2026$59.43M+4.4%−$1.18M−2.0%−$0.08−$5.04M
FY2025ended Apr 30, 2025$56.94M+13.5%$4.70M8.3%$0.33$7.00M
FY2024ended Apr 30, 2024$50.16M−6.9%−$7.28M−14.5%−$0.54−$6.97M
FY2023ended Apr 30, 2023$53.87M+9.7%−$5.34M−9.9%−$0.39$1.10M
FY2022ended Apr 30, 2022$49.11M+19.7%$548.00K1.1%$0.04$4.11M
FY2021ended Apr 30, 2021$41.04M+27.8%$362.00K0.9%$0.02−$4.96M
FY2020ended Apr 30, 2020$32.12M+1,007.7%−$2.09M−6.5%−$0.18$685.00K
FY2019ended Apr 30, 2019$2.90M−85.7%$128.00K4.4%$0.01$1.03M
FY2018ended Apr 30, 2018$20.24M+31.3%−$1.48M−7.3%−$0.13−$2.46M
FY2017ended Apr 30, 2017$15.41M—−$6.88M−44.7%−$0.64−$3.61M
Champions Oncology quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q1 FY2027ended Jul 31, 2026$15.23M−$426.00K—
Q4 FY2026ended Apr 30, 2026$13.84M−$698.00K−$0.05
Q3 FY2026ended Jan 31, 2026$16.56M−$279.00K−$0.02
Q2 FY2026ended Oct 31, 2025$15.04M$268.00K$0.02
Q1 FY2026ended Jul 31, 2025$14.00M−$466.00K−$0.03
Q4 FY2025ended Apr 30, 2025$12.36M−$1.84M−$0.12
Q3 FY2025ended Jan 31, 2025$17.04M$4.50M$0.31
Q2 FY2025ended Oct 31, 2024$13.49M$728.00K$0.05

Company profile

Name
Champions Oncology, Inc.
Ticker
CSBR
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
855 N. Wolfe Street, Suite 619, Baltimore, MD 21205
Incorporated in
DE
Fiscal year ends
April
SEC CIK
0000771856

Recent SEC filings

Frequently asked questions

What is Champions Oncology's stock price?

Champions Oncology (CSBR) closed at $400.01 on Oct 9, 2026, down 0.50% from the previous close of $402.02.

What is Champions Oncology's market cap?

Champions Oncology's market cap is $5.57B, based on a share price of $400.01 and 13.9M shares outstanding as of Jul 31, 2026.

How much revenue does Champions Oncology make?

Champions Oncology reported revenue of $59.43M for fiscal 2026, up 4.36% from fiscal 2025.

Does Champions Oncology pay a dividend?

Champions Oncology's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Champions Oncology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures